Related Experiment Video
Updated: Jul 16, 2026

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells
Andrew D Slack1, Zaowen Chen, Andrew D Ludwig
1Center for Cell and Gene Therapy, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA.
Abstract:
The MYC family oncogenes cause transformation and tumor progression by corrupting multiple cellular pathways, altering cell cycle progression, apoptosis, and genomic instability. Several recent studies show that MYCC (c-Myc) expression alters DNA repair mechanisms, cell cycle checkpoints, and karyotypic stability, and this is likely partially due to alterations in centrosome replication control. In neuroblastoma cell lines, MYCN (N-Myc) expression induces centrosome amplification in response to ionizing radiation. Centrosomes are cytoplasmic domains that critically regulate cytokinesis, and aberrations in their number or structure are linked to mitotic defects and karyotypic instability. Whereas centrosome replication is linked to p53 and Rb/E2F-mediated cell cycle progression, the mechanisms downstream of MYCN that generate centrosome amplification are incompletely characterized. We hypothesized that MDM2, a direct transcriptional target of MYCN with central inhibitory effects on p53, plays a role in MYC-mediated genomic instability by altering p53 responses to DNA damage, facilitating centrosome amplification. Herein we show that MYCN mediates centrosome amplification in a p53-dependent manner. Accordingly, inhibition of the p53-MDM2 interaction with Nutlin 3A (which activates p53) completely ablates the MYCN-dependent contribution to centrosome amplification after ionizing radiation. We further show that modulating MDM2 expression levels by overexpression or RNA interference-mediated posttranscriptional inhibition dramatically affects centrosome amplification in MYCN-induced cells, indicating that MDM2 is a necessary and sufficient mediator of MYCN-mediated centrosome amplification. Finally, we show a significant correlation between centrosome amplification and MYCN amplification in primary neuroblastoma tumors. These data support the hypothesis that elevated MDM2 levels contribute to MYCN-induced genomic instability through altered regulation of centrosome replication in neuroblastoma.
Insights
MYCN oncogene drives neuroblastoma tumor growth by causing centrosome amplification, a key factor in genomic instability. MDM2 protein mediates this effect, highlighting a potential therapeutic target for neuroblastoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MYC family oncogenes, including MYCN, are crucial drivers of tumor progression and genomic instability.
- Centrosome amplification, linked to mitotic defects and karyotypic instability, is observed in MYCN-expressing neuroblastoma cells.
- The precise mechanisms by which MYCN induces centrosome amplification remain incompletely understood.
Purpose of the Study:
- To investigate the role of MDM2 in MYCN-mediated centrosome amplification and genomic instability in neuroblastoma.
- To determine if p53 pathway modulation affects MYCN-induced centrosome amplification.
Main Methods:
- Utilized neuroblastoma cell lines with varying MYCN expression levels.
- Employed ionizing radiation to induce DNA damage and assess centrosome amplification.
- Investigated the effect of MDM2 modulation (overexpression and RNA interference) and p53-MDM2 interaction inhibition (Nutlin 3A) on centrosome amplification.
- Correlated centrosome amplification with MYCN amplification in primary neuroblastoma tumors.
Main Results:
- MYCN expression mediates centrosome amplification in a p53-dependent manner.
- Inhibition of the p53-MDM2 interaction with Nutlin 3A abrogated MYCN-dependent centrosome amplification.
- MDM2 overexpression or inhibition significantly modulated centrosome amplification in MYCN-expressing cells, establishing MDM2 as a necessary and sufficient mediator.
- A significant correlation was found between centrosome amplification and MYCN amplification in primary neuroblastoma tumors.
Conclusions:
- MDM2 is a critical mediator of MYCN-induced centrosome amplification in neuroblastoma.
- Targeting the p53-MDM2 interaction may represent a therapeutic strategy to reduce MYCN-driven genomic instability in neuroblastoma.
- Elevated MDM2 levels contribute to MYCN-induced genomic instability by dysregulating centrosome replication.
Related Concept Videos
Abnormal Proliferation
Induced Pluripotent Stem Cells
Somatic cells are...
Inhibition of Cdk Activity
Negative Regulator Molecules
Centrosome Duplication
To ensure that each daughter cell receives a centrosome after cell division, centrosome duplication...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
